Fundraising Fox

Twist Bioscience

NASDAQ: TWST

South San Francisco, US · Founded 2013 · Delaware corporation · 1,308 employees on LinkedIn · Public · 14 known investors

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals. The platform enables faster and more affordable DNA synthesis at scale with customizable high-throughput capabilities.

Also known as Twist · TWST

Founders & leadership

Twist Bioscience was founded in 2013 by Emily Marine Leproust, William Charles Banyai, Bill James Peck, and Emily Leproust.

EMEmily Marine Leproust
Emily Marine LeproustCo-founder
WC
William Charles BanyaiCo-founder
BJ
Bill James PeckCo-founder
ELEmily Leproust
Emily Leproustin𝕏Co-founder · CEOEmily Leproust is co-founder and CEO of Twist Bioscience, which develops a silicon-based synthetic DNA manufacturing platform for applications in medicine, diagnostics, agriculture, and industrial chemistry. Before Twist, she led technology development at Agilent Technologies, including the SureSelect product line and Oligo Library Synthesis technology, and she serves on the boards of GeneDx, Atlas Data Storage, and the Nuclear Threat Initiative while also co-founding the biotech accelerator Petri.

Board

KCKeith Crandell
Keith CrandellBoard directorCo-founder & Managing Director at ARCH Venture Partners
PCPaul Conley
Paul Conleyin𝕏fmr Board Member (NASDAQ: TWST)Chairman & CEO at GENERAL INCEPTION
FCFred Craves
Fred CravesinBoard directorManaging Director at Bay City Capital
RC
Rob ChessBoard director

Investors · 14

Reported raises · per SEC filings

Form D private placements

$260.8M disclosed across 7 rounds · 2013–2018

$50MraisedApr 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith CrandellDirector
  • Paul ConleyDirector
  • Bob RagusaDirector
  • Minqi LiDirector
  • Rob ChessDirector
  • William BanyaiExecutive Officer, Director
  • Fred CravesDirector
  • Bill PeckExecutive Officer
  • Emily Marine LeproustExecutive Officer, Director
Offering amount
$85M
Amount sold
$50M
First sale
Mar 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$74.9MraisedDec 2017 · 63 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith CrandellDirector
  • Bill PeckExecutive Officer
  • Paul ConleyDirector
  • Emily Marine LeproustExecutive Officer, Director
  • Bob RagusaDirector
  • Rob ChessDirector
  • Fred CravesDirector
  • William BanyaiExecutive Officer, Director
Offering amount
$75M
Amount sold
$74.9M
First sale
Mar 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2.6MraisedApr 2016 · 46 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith CrandellDirector
  • William Charles BanyaiExecutive Officer, Director
  • Paul ConleyDirector
  • Solange GlaizeExecutive Officer
  • Rob ChessDirector
  • Fred CravesDirector
  • Bill James PeckExecutive Officer
  • Emily Marine LeproustExecutive Officer, Director
  • Nick NaclerioDirector
Offering amount
$2.6M
Amount sold
$2.6M
First sale
Apr 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$61MraisedJan 2016 · 35 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Emily Marine LeproustExecutive Officer, Director, Promoter
  • William Charles BanyaiExecutive Officer, Director, Promoter
  • Paul ConleyDirector
  • Nick NaclerioDirector
  • Rob ChessDirector
  • Keith CrandellDirector
  • Fred CravesDirector
  • Bill James PeckExecutive Officer, Promoter
Offering amount
$61M
Amount sold
$61M
First sale
Jan 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$37MraisedJun 2015 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith CrandellDirector
  • Paul ConleyDirector
  • Fred CravesDirector
  • Emily Marine LeproustExecutive Officer, Director, Promoter
  • William Charles BanyaiExecutive Officer, Director, Promoter
  • Bill James PeckExecutive Officer, Promoter
  • Rob ChessDirector
Offering amount
$37M
Amount sold
$37M
First sale
May 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$26MraisedMay 2014 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William Charles BanyaiExecutive Officer, Director
  • Keith CrandellDirector
  • Bill James PeckExecutive Officer
  • Paul ConleyDirector
  • Fred CravesDirector
  • Emily Marine LeproustExecutive Officer, Director
Offering amount
$26.5M
Amount sold
$26M
First sale
May 2014
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$9.1MraisedFeb 2014 · 16 investors · Other Technology
Rule 506(c)
Officers, directors & promoters on the filing
  • Keith CrandellDirector
  • Emily Marine LeproustExecutive Officer, Director
  • William Charles BanyaiExecutive Officer, Director
  • Paul ConleyDirector
  • Bill James PeckExecutive Officer
Offering amount
$9.3M
Amount sold
$9.1M
First sale
Jul 2013
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Company profile

researched Aug 2026

Twist Bioscience is a biotechnology company headquartered in South San Francisco, California that manufactures synthetic DNA and DNA-derived products for customers across a range of industries [7]. Its catalog spans arrayed and pooled genes (clonal genes, gene fragments, gene pools, multiplexed gene fragments), oligo pools and cloned oligo pools, and variant libraries including TCR libraries, combinatorial variant libraries, site saturation libraries and enzyme screening kits [0][1].

A second major product line covers next-generation sequencing (NGS) workflows: target enrichment panels (custom panels, Exome 2.0, DNA comprehensive genomic profiling, RNA Exome, Human Methylome), hybridization solutions and enzymes such as TrueAmp Polymerase Mix, library preparation kits (TrueAmp, PCR-free WGS, cfDNA, RNA, EM-seq v2 methylation detection), and synthetic controls such as cfDNA pan-cancer reference standards and respiratory and monkeypox virus controls [0][1]. Through Twist Biopharma Solutions the company offers antibody discovery and engineering services, including in vitro and in vivo discovery, antibody optimization, production and characterization, bispecific and VHH antibodies, plus pipeline licensing and partnerships [3][4]. The site also lists IVDR solutions, an ordering platform with a Twist API and procurement integrations, and an NGS ProLab certified services program [0][1].

Business model

Twist sells synthetic DNA products and NGS reagents/kits directly through an online ordering platform (including API and procurement-system integrations) and via channel partners and distributors, and additionally provides antibody discovery and characterization services to biopharma customers under partnership, collaboration and licensing arrangements [0][1][3].

Traction

Wikipedia cites revenue of $54.2 million for 2019 and approximately 400 employees [7]. Company materials cite antibody discovery throughput of more than 6,000 IgGs per week with full characterization data in as few as 15 days [0][1][3].

Latest developments

Recent or newly flagged products on the company site include the TrueAmp Library Preparation Kit, cfDNA Library Prep Kit and cfDNA Pan-Cancer Reference Standard v2, EM-seq v2 methylation detection system, Human Methylome panel, multiplexed gene fragments, TCR libraries, enzyme screening kits and an MRD Express offering [0][1].

Full profile — market position, technology, go-to-market, geography, history, risks & controversies

Market position

Described as a synthetic biology company manufacturing DNA sequences and a manufacturer of synthetic DNA products serving a wide range of industries [6][7]; it is a component of the Russell 2000 index [7].

Technology

The company's offering is built on synthetic DNA manufacturing, supported by sequence design tools including a Sequence Design Workbench, Manufacturability Analyzer, Codon Optimizer and vector toolbox, and by proprietary reagents such as the TrueAmp library preparation chemistry described as delivering uniformity across GC-rich, AT-rich and repeat-dense regions [0][1]. In May 2021 Twist and Genome Project-Write launched a CAD platform for whole genome design intended to automate workflows spanning plasmids to megabase-scale genomes [7].

Go-to-market

Direct e-commerce ordering with sign-in accounts, an API and procurement integrations, an "NGS ProLab" certified service provider program, and a network of channel partners and distributors; multilingual site support (English, Chinese, Japanese, Spanish) indicates international selling [0][1].

Research and clinical customers in synthetic biology, cancer research and clinical oncology (including liquid biopsy and minimal residual disease), infectious disease research, agricultural biotechnology, drug discovery and AI-driven drug discovery [0][1][4].

Geography

Headquartered in South San Francisco, California [6][7]; the customer-facing site is offered in English, Chinese, Japanese and Spanish [0][1].

History

Founded in 2013 by Emily Leproust, Bill Banyai and Bill Peck [7]. Leproust represented the company at a March 2021 tabletop exercise at the Munich Security Conference simulating a weaponized monkeypox outbreak [7]. In May 2021 Twist and Genome Project-Write launched a CAD platform for whole genome design [7]. The company is now publicly traded on Nasdaq as TWST [7].

Risks & controversies

One aggregator source reports a $120M Series D at a $1.5B valuation dated September 2025 with Greylock Partners, Founders Fund and Kleiner Perkins, and total funding of $350M; these figures are internally inconsistent (headline total raised of $120M versus $350M) and conflict with the company's public-market status, so they should be treated as low confidence [6].

Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
EmployeesJan 2026400 people
RevenueJan 2019$54.2M

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Founder mafia

3 people who came through Twist Bioscience went on to found or lead other companies.

+ 1 more

Competitors · 2

by search overlap

Companies competing with Twist Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.

Timeline · 2

launches, deals, and filings
May 2021
CAD platform for whole genome design launched with Genome Project-Write

Twist Bioscience and Genome Project-Write launched a computer-aided design platform to automate whole genome design workflows, from plasmids to megabase-scale genomes.

source ↗

Mar 2021
Participation in Munich Security Conference biosecurity tabletop exercise

Twist Bioscience, represented by Emily Leproust, took part in a tabletop exercise simulating an outbreak of weaponized monkeypox.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

Legal entities · 1

corporate structure
Twist BioscienceDelaware

In the news

Research sources · 8

primary sources listed

8 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Twist Bioscience do?
Nasdaq-listed synthetic biology company (TWST) manufacturing synthetic DNA, genes, NGS tools and antibody discovery services.
Who founded Twist Bioscience?
Twist Bioscience was founded by Emily Marine Leproust, William Charles Banyai, Bill James Peck, Emily Leproust in 2013.
Who are Twist Bioscience's investors?
Twist Bioscience's investors include +ND Capital, 3E Bioventures Capital, ARCH Venture Partners, Asset Management Company, Bay City Capital, Black Opal Ventures, Dentsu Ventures, iGlobe Partners and 6 more.
How much funding has Twist Bioscience raised?
Twist Bioscience has disclosed $260.8M raised across 7 rounds.
Is Twist Bioscience publicly traded?
Yes — Twist Bioscience trades on NASDAQ under the ticker TWST.
Where is Twist Bioscience headquartered?
Twist Bioscience is headquartered in South San Francisco, US.